Maalox (aluminum hydroxide/simethicone/magnesium hydroxide) / Sanofi 
Welcome,         Profile    Billing    Logout  
 19 Diseases   1 Trial   1 Trial   109 News 


12»
  • ||||||||||  Maalox (aluminum hydroxide/simethicone/magnesium hydroxide) / Sanofi
    Unique Case of Vanishing Bile Duct Syndrome Exacerbated by Noncompliance (Exhibit Hall E) -  Aug 20, 2024 - Abstract #ACG2024ACG_5261;    
    The patient was prescribed both amoxicillin and amoxicillin-clavulanic acid within a 3 month period which points to dose-dependent cause, which differs from the more documented idiosyncratic cause. This case was unique because of the exacerbated nature of disease due to noncompliance.
  • ||||||||||  Maalox (aluminum hydroxide/simethicone/magnesium hydroxide) / Sanofi
    Clinical, Review, Journal:  Supportive care and antiviral treatments in primary herpetic gingivostomatitis: a systematic review. (Pubmed Central) -  Nov 8, 2023   
    This case was unique because of the exacerbated nature of disease due to noncompliance. Out of the five studies included in this systematic review, only one was able to provide some weak evidence that ACV is an effective treatment, improving healing of oral lesions and reducing duration of symptoms.
  • ||||||||||  Maalox (aluminum hydroxide/simethicone/magnesium hydroxide) / Sanofi, Carafate (sucralfate) / AbbVie
    Rare Incidence of Granular Cell Tumor in the Esophagus Causing Obstructive and Reflux Symptoms (Exhibit Hall) -  Jul 29, 2023 - Abstract #ACG2023ACG_3826;    
    Symptoms were uncontrolled despite home medications including pantoprazole, famotidine, Maalox and sucralfate as well as a high fiber diet...He further reported episodes of constipation for which he was started on metoclopramide...There was sonographic evidence suggesting parenchymal invasion into the trachea (manifested by abutment). Figure 1c: Endoscopic ultrasound guided core biopsy of the esophageal lesion using H&E Stain shows diffuse proliferation of uniform epithelioid cells with abundant eosinophilic granular cytoplasm and small nuclei in muscularis propria (blue arrow), consistent with a granular cell tumor.
  • ||||||||||  elcubragistat (Lu AG06466) / Lundbeck
    Trial completion:  A Study to Evaluate a New Tablet Formulation of Lu AG06466 in Healthy Participants (clinicaltrials.gov) -  Jan 20, 2022   
    P1,  N=16, Completed, 
    In addition, pH-modifying comedications were not found to alter the pharmacokinetics of finerenone and were deemed safe for co-administration. Recruiting --> Completed
  • ||||||||||  Maalox (aluminum hydroxide/simethicone/magnesium hydroxide) / Sanofi
    Preclinical, Journal:  Oral absorption and drug interaction kinetics of moxifloxacin in an animal model of weightlessness. (Pubmed Central) -  Oct 2, 2021   
    These interactions showed dose staggering when oral administrations of Pepto-Bismol and moxifloxacin were separated by 60 min in control rats but not in TS rats. Dose staggering was more apparent after the coadministration of Maalox and moxifloxacin in TS rats.
  • ||||||||||  Maalox (aluminum hydroxide/simethicone/magnesium hydroxide) / Sanofi, Carafate (sucralfate) / AbbVie
    Journal:  Effects of Magnesium, Calcium, and Aluminum Chelation on Fluoroquinolone Absorption Rate and Bioavailability: A Computational Study. (Pubmed Central) -  May 1, 2021   
    Quantum mechanical calculations elucidated FQ-metal binding energies, which were leveraged to predict the magnitude of reduced bioavailability via a quantitative structure-property relationship (QSPR). This work will help inform clinical FQ formulation design, alert to possible dietary effects, and shed light on drug-drug interactions resulting from coadministration at an earlier stage in the drug development pipeline.
  • ||||||||||  Maalox (aluminum hydroxide/simethicone/magnesium hydroxide) / Sanofi
    [VIRTUAL] Comparing Clinical Outcomes of GI Cocktail versus Antacid alone () -  Dec 26, 2020 - Abstract #ASHP2020ASHP_1229;    
    One previous double-blinded study compared Mylanta alone, Mylanta and Donnatal, or Mylanta, Donnatal and lidocaine to assess which combination provided the most relief of dyspepsia in emergency room patients. Their results concluded that the addition of Donnatal or Donnatal plus lidocaine did not significantly relieve dyspepsia more than antacid alone4.
  • ||||||||||  Maalox (aluminum hydroxide/simethicone/magnesium hydroxide) / Sanofi, Carafate (sucralfate) / AbbVie
    [VIRTUAL] Spontaneous Intramural Hematoma of the Esophagus Presenting With Chest Pain () -  Sep 15, 2020 - Abstract #ACG2020ACG_1624;    
    She was started on Carafate and Maalox for symptomatic relief and discharged after resolution of her presenting symptoms...Surgery and therapeutic angiography are reserved for patients who are hemodynamically unstable. Ultimately, IHE is an important entity to identify since conservative management is appropriate in most cases and patients can be reassured of its benign nature.
  • ||||||||||  Maalox (aluminum hydroxide/simethicone/magnesium hydroxide) / Sanofi
    Clinical, Journal, Adverse drug reaction:  Caveat Medicus: Clinician experiences in publishing reports of serious oncology-associated adverse drug reactions. (Pubmed Central) -  Jul 16, 2020   
    Big data, registries, Data Safety Monitoring Boards, and pharmacogenetic studies may facilitate improved pharmacovigilance efforts for oncology-associated adverse drug reactions. These initiatives overcome concerns related to complacency, indifference, ignorance, and system-level problems as barriers to documenting and reporting adverse drug events- barriers that have been previously reported for clinician reporting of serious adverse drug reactions.
  • ||||||||||  Maalox (aluminum hydroxide/simethicone/magnesium hydroxide) / Sanofi
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  TPvsM: Effect of Over-the-counter Toothpastes on Chemotherapy-induced Oral Mucositis (clinicaltrials.gov) -  Feb 6, 2019   
    P2,  N=1, Terminated, 
    These initiatives overcome concerns related to complacency, indifference, ignorance, and system-level problems as barriers to documenting and reporting adverse drug events- barriers that have been previously reported for clinician reporting of serious adverse drug reactions. N=82 --> 1 | Trial completion date: Dec 2019 --> Feb 2019 | Recruiting --> Terminated | Trial primary completion date: Dec 2019 --> Feb 2019; Lack of enrollment
  • ||||||||||  Maalox (aluminum hydroxide/simethicone/magnesium hydroxide) / Sanofi
    Enrollment open:  TPvsM: Effect of Over-the-counter Toothpastes on Chemotherapy-induced Oral Mucositis (clinicaltrials.gov) -  Jun 3, 2018   
    P2,  N=82, Recruiting, 
    N=82 --> 1 | Trial completion date: Dec 2019 --> Feb 2019 | Recruiting --> Terminated | Trial primary completion date: Dec 2019 --> Feb 2019; Lack of enrollment Not yet recruiting --> Recruiting
  • ||||||||||  Maalox (aluminum hydroxide/simethicone/magnesium hydroxide) / Sanofi
    Trial completion date, Trial primary completion date:  TPvsM: Effect of Over-the-counter Toothpastes on Chemotherapy-induced Oral Mucositis (clinicaltrials.gov) -  Apr 5, 2018   
    P2,  N=82, Not yet recruiting, 
    Not yet recruiting --> Recruiting Trial completion date: Jul 2019 --> Dec 2019 | Trial primary completion date: Jan 2019 --> Dec 2019
  • ||||||||||  Maalox (aluminum hydroxide/simethicone/magnesium hydroxide) / Sanofi
    Trial initiation date, Trial primary completion date:  TPvsM: Effect of Over-the-counter Toothpastes on Chemotherapy-induced Oral Mucositis (clinicaltrials.gov) -  Aug 31, 2017   
    P2,  N=82, Not yet recruiting, 
    Trial completion date: Jul 2019 --> Dec 2019 | Trial primary completion date: Jan 2019 --> Dec 2019 Initiation date: Jul 2016 --> Jan 2018 | Trial primary completion date: Jun 2018 --> Jan 2019
  • ||||||||||  Isentress (raltegravir) / Merck (MSD)
    Phase classification:  Effect of Antacids on the Pharmacokinetics of Raltegravir (clinicaltrials.gov) -  Jun 28, 2017   
    P1,  N=17, Completed, 
    Initiation date: Jul 2016 --> Jan 2018 | Trial primary completion date: Jun 2018 --> Jan 2019 Phase classification: P=N/A --> P1
  • ||||||||||  Maalox (aluminum hydroxide/simethicone/magnesium hydroxide) / Sanofi
    Enrollment change, Trial initiation date, Trial primary completion date:  TPvsM: Effect of Over-the-counter Toothpastes on Chemotherapy-induced Oral Mucositis (clinicaltrials.gov) -  Apr 13, 2016   
    P2,  N=82, Not yet recruiting, 
    Phase classification: P=N/A --> P1 N=30 --> 82 | Initiation date: Jan 2016 --> Jul 2016 | Trial primary completion date: Jun 2016 --> Jun 2018
  • ||||||||||  Isentress (raltegravir) / Merck (MSD)
    Trial completion:  The Effect of Antacids and Multivitamins on Raltegravir (clinicaltrials.gov) -  Feb 26, 2016   
    P1,  N=15, Completed, 
    N=30 --> 82 | Initiation date: Jan 2016 --> Jul 2016 | Trial primary completion date: Jun 2016 --> Jun 2018 Active, not recruiting --> Completed
  • ||||||||||  Isentress (raltegravir) / Merck (MSD)
    Enrollment closed, Trial primary completion date:  The Effect of Antacids and Multivitamins on Raltegravir (clinicaltrials.gov) -  Jan 11, 2016   
    P1,  N=15, Active, not recruiting, 
    Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2015 --> Mar 2016
  • ||||||||||  imatinib / Generic mfg.
    Phase classification:  Effect of Antacids on Gleevec (clinicaltrials.gov) -  Jan 7, 2016   
    P1,  N=12, Completed, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2015 --> Mar 2016 Phase classification: P=N/A --> P1
  • ||||||||||  Isentress (raltegravir) / Merck (MSD)
    Trial primary completion date:  The Effect of Antacids and Multivitamins on Raltegravir (clinicaltrials.gov) -  Sep 24, 2015   
    P1,  N=15, Recruiting, 
    Phase classification: P=N/A --> P1 Trial primary completion date: Aug 2015 --> Nov 2015
  • ||||||||||  Maalox (aluminum hydroxide/simethicone/magnesium hydroxide) / Sanofi, Auryxia (ferric citrate) / Japan Tobacco, Akebia Therap, Fosrenol (lanthanum carbonate) / Takeda
    Enrollment open, Trial initiation date, Trial primary completion date:  Optimal Anemia Treatment in End Stage Renal Disease (ERSD) (clinicaltrials.gov) -  Sep 17, 2015   
    P=N/A,  N=50, Recruiting, 
    Trial primary completion date: Aug 2015 --> Nov 2015 Not yet recruiting --> Recruiting | Initiation date: Nov 2014 --> Mar 2015 | Trial primary completion date: May 2016 --> Dec 2016
  • ||||||||||  Isentress (raltegravir) / Merck (MSD)
    Trial primary completion date:  The Effect of Antacids and Multivitamins on Raltegravir (clinicaltrials.gov) -  Jun 11, 2015   
    P1,  N=15, Recruiting, 
    Not yet recruiting --> Recruiting | Initiation date: Nov 2014 --> Mar 2015 | Trial primary completion date: May 2016 --> Dec 2016 Trial primary completion date: May 2015 --> Aug 2015